Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 31, Issue 4, Pages 396-400Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2018.09.013
Keywords
Acute myeloid leukemia; AML; Assay; MFC; Multi-parameter flow cytometry; Minimal/measurable residual disease; MRD; Next-generation sequencing; NGS; Reverse-transcriptase-polymerase-chain reaction; RT-PCR
Categories
Ask authors/readers for more resources
Interest in detecting minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) has been increasing, but numerous issues need to be addressed if MRD assessment is to be routinely incorporated into practice. Assays, their reliability, standardization, and availability all must be considered, and a strategy developed to eradicate residual leukemia. This paper reviews some issues surrounding the routine incorporation of MRD assessment into practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available